预约演示
更新于：2025-08-20
Terbinafine Hydrochloride
盐酸特比萘芬
更新于：2025-08-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H26ClN |
InChIKeyBWMISRWJRUSYEX-SZKNIZGXSA-N |
CAS号78628-80-5 |
关联
82
项与 盐酸特比萘芬 相关的临床试验TCTR20250319015
Efficacy and Safety of 1% Terbinafine Film-Forming Solution Single Application versus 1% Clotrimazole Cream Standard Dose in the Treatment of Tinea Pedis in Correctional Setting
NCT07068256
Comparison Between Therapeutic Efficacy of Itraconazole Pulse Therapy and Terbinafine Therapy in Treatment of Tinea Capitis in Pediatric Population.
NCT06400056
Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis
100 项与 盐酸特比萘芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的专利（医药）
登录后查看更多信息
2,157
项与 盐酸特比萘芬 相关的文献（医药）2025-12-31JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Hidden targets in dermatology:
In vitro
and
In silico
inhibitory effects of common 23 dermatologic drugs on human carbonic anhydrase isoenzymes I and II
Article
作者: Uslu, Harun ; Çıkrıkcı, Kübra ; Can, İlkay ; Gençer, Nahit
In this study, we have aimed to determine the in vitro and in silico effects of 23 frequently used dermatologic drugs on human carbonic anhydrase I (hCA I) and II (hCA II). The inhibitory effects of the drugs on hCA I and hCA II were determined by esterase methods. The most potent inhibitors were isotretinoin for hCA I (Ki= 5.75 µM) and valaciclovir for hCA II (Ki= 5.74 µM). Ketotifen (Ki= 6.98 µM), pantoprazole (Ki= 7.16 µM) and acyclovir (Ki= 7.31 µM) were also potent inhibitors for hCA I. Isotretinoin (Ki= 6.54 µM), brivudine (Ki= 7.44 µM) and fluconazole (Ki= 7.91 µM) were also potent inhibitors for hCA II. Terbinafine hydrochloride was a weak CA inhibitor for both of these isoenzymes (Ki= 20.58 µM for hCA I and 20.32 µM for hCA I). Therefore, the drug, having a weak CA inhibitory activity, may be preferred primarily in patients with a skin disease compared to the other drugs due to important physiological functions of CAs. Molecular docking studies have shown that acitretin and isotretinoin, in particular, will inhibit hCA I at lower concentrations and have higher docking scores. For hCA II, it was shown that Isotretinoin and Ketotifen would inhibit at lower concentrations and have higher placement scores.
2025-07-03Expert Opinion On Drug Safety
Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus
Review
作者: Wang, Chunjiang ; Guo, Yuge ; He, Yang ; Ouyang, Linqi ; He, Yiran ; Fan, Zhiqiang
INTRODUCTION:
Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics.
METHODS:
We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included.
RESULTS:
The patients have a median age of 49.5 years (range 18-79) and onset time of 5 weeks (range 1-12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7-84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5-48) of follow-up.
CONCLUSION:
These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.
2025-06-01CURRENT MICROBIOLOGY
Fungal Infections Resulting From Prolonged Use of Personal Protective Equipment
Article
作者: Berikten, Derya ; Aydin, Elif ; Renders, Duygu Percin ; Utku, Selve Arslan
This study is the first to investigate fungal infections resulting from prolonged use of personal protective equipment (PPE) among healthcare workers at Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital, during the COVID-19 pandemic. The research aimed to isolate, molecularly type, and assess the antifungal susceptibility of superficial fungal infection agents associated with PPE use. Additionally, the relationship between these fungi and PPE use was evaluated through a questionnaire. Samples were collected from 100 healthcare workers experiencing skin issues. Among them, all N95/FFP2 mask users, 44.3% of glove users, 36.1% of surgical mask users, and 22.9% of hair cap users reported skin reactions, with acne (n = 34) being the most common. Identified fungal isolates included Trametes hirsuta, Penicillium chrysogenum, Aspergillus fumigatus, Rhodotorula sp., Candida sp., Pichia fermentans, and the dermatophyte Microsporum ferrugineum. Antifungal susceptibility tests revealed 47.6% resistance to fluconazole and 76.2% resistance to voriconazole (n = 16). This study provides the first institutional data on PPE-associated fungal infections and antifungal resistance in healthcare settings. These findings highlight the dermatological risks of prolonged PPE use. To mitigate these effects, healthcare institutions should prioritize high-quality materials, establish optimal usage guidelines, and provide continuous training on self-protection.
100 项与 盐酸特比萘芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲癣 | 澳大利亚 | 2003-12-22 | |
| 体癣 | 澳大利亚 | 2003-12-22 | |
| 股癣 | 澳大利亚 | 2003-12-22 | |
| 足癣 | 美国 | 1999-03-09 | |
| 皮肤真菌病 | 中国 | 1997-01-01 | |
| 皮肤念珠菌病 | 日本 | 1993-07-02 | |
| 真菌病 | 日本 | 1993-07-02 | |
| 癣 | 日本 | 1993-07-02 | |
| 花斑癣 | 日本 | 1993-07-02 | |
| 头癣 | 美国 | 1992-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 红斑 | 临床1期 | 美国 | 2017-10-15 | |
| 粘膜念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| 口腔念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| HIV感染 | 临床阶段不明 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 384 | 繭襯選選鏇遞構觸築網(襯鏇鬱獵襯壓繭鏇窪襯) = 選夢遞製窪膚簾艱選壓 廠襯窪簾艱選窪鬱窪範 (醖鬱膚糧憲構網範製糧 ) 更多 | 不佳 | 2025-01-10 | |||
临床1期 | 20 | 鏇鑰壓艱製鹹窪壓繭築(餘憲簾廠醖窪廠艱願願) = Adverse events (five patients), such as headache (n = 3), seasonal allergy (n = 1), and neck pain (n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. 鑰繭獵糧簾襯觸齋遞憲 (鏇獵顧積壓憲鏇淵壓繭 ) | 积极 | 2024-08-19 | |||
临床3期 | - | 積憲壓鑰顧夢觸淵鏇壓(夢齋範選積醖顧獵膚繭) = 壓壓膚範鹹獵憲顧糧襯 積憲積築淵餘積構鏇夢 (醖鑰鬱齋壓餘憲鹽餘積 ) 更多 | 非优 | 2021-07-01 | |||
vehicle | 積憲壓鑰顧夢觸淵鏇壓(夢齋範選積醖顧獵膚繭) = 鬱積憲獵顧淵鑰窪選繭 積憲積築淵餘積構鏇夢 (醖鑰鬱齋壓餘憲鹽餘積 ) 更多 | ||||||
临床3期 | 452 | 製繭網觸簾簾築構製繭(鏇夢襯蓋獵簾壓積餘範) = 膚淵構網獵艱窪壓憲襯 蓋淵窪齋鬱餘鹽廠壓糧 (齋繭繭廠廠鹹願積築夢 ) 更多 | 非劣 | 2020-06-25 | |||
製繭網觸簾簾築構製繭(鏇夢襯蓋獵簾壓積餘範) = 鹽選範齋製齋淵範膚糧 蓋淵窪齋鬱餘鹽廠壓糧 (齋繭繭廠廠鹹願積築夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用